ArticleJournal of oncology2019
The Financial Impact of Hypofractionated Radiation for Localized Prostate Cancer in the United States.
Article in Journal of oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Hypofractionated Postprostatectomy Radiation Therapy for Prostate Cancer to Reduce Toxicity and Improve Patient Convenience: A Phase 1/2 Trial.International journal of radiation oncology, biology, physics · 2021Trial
- Article
- From fractionation to financials: economic and clinical implications of hypofractionation in German outpatient radiotherapy practice.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- Geographic and Physician-Level Variation in the Use of Hypofractionated Radiation Therapy for Breast Cancer in the U.S.: A Cross-Classified Multilevel Analysis.Advances in radiation oncology · 2024Article
- Trends in Utilization and Medicare Spending on Short-Course Radiation Therapy for Breast and Prostate Cancer: An Episode-Based Analysis From 2015 to 2019.International journal of radiation oncology, biology, physics · 2024Article
- Review
- Hypofractionated Radiotherapy in Gynecologic Malignancies-A Peek into the Upcoming Evidence.Cancers · 2024Review
- Hypofractionated Radiotherapy for Hematologic Malignancies during the COVID-19 Pandemic and Beyond.Current oncology (Toronto, Ont.) · 2024Article
- Hypofractionation Adoption in Prostate Cancer Radiotherapy: Results of an International Survey.JCO global oncology · 2023Article
- Moderately hypofractionated radiotherapy as definitive treatment for localized prostate cancer: Pattern of practice in German-speaking countries : A survey of the Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party on Radiation Oncology of the German Cancer Society (DKG-ARO).Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2021Article
- Practical considerations for prostate hypofractionation in the developing world.Nature reviews. Urology · 2021Review
- Analysis of Price Transparency via National Cancer Institute-Designated Cancer Centers' Chargemasters for Prostate Cancer Radiation Therapy.JAMA oncology · 2020Article
- Refinement & validation of rectal wall dose volume objectives for prostate hypofractionation in 20 fractions.Clinical and translational radiation oncology · 2020Article
- Robotic Stereotactic Body Radiation Therapy for the Adjuvant Treatment of Early-Stage Breast Cancer: Outcomes of a Large Single-Institution Study.Advances in radiation oncologyArticle
- Cost Comparison From a Patient Perspective for Intracranial Stereotactic Radiation Therapy.Advances in radiation oncologyArticle
- A Phase 1 Trial of Highly Conformal, Hypofractionated Postprostatectomy Radiation Therapy.Advances in radiation oncologyArticle
- The Case for Brachytherapy: Why It Deserves a Renaissance.Advances in radiation oncologyArticle
- Moderately Hypofractionated Radiation for Benign Meningiomas and Schwannomas: A Report of 70 Patients Treated Between 2008 and 2018.Advances in radiation oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUntil recently, dose intensified radiotherapy was the standard radiation method for localized prostate cancer. Multiple studies have demonstrated similar efficacy and tolerability with moderate hypofractionation. In recent years there has been an increasing focus placed on understanding the cost and value of cancer care. In this study we aimed to assess the economic impact of moderate hypofractionation for payers in the United States.
methodsWe performed a population-based analysis of the total cost of external beam radiotherapy (EBRT) for localized prostate cancer in the US annually. The national annual target population of patients treated with definitive EBRT was calculated using the Surveillance, Epidemiology, and End Results (SEER) database. Treatment costs for various fractionation schemes were based on billing codes and 2018 pricing by the Centers for Medicare and Medicaid Services (CMS).
resultsWe estimate that 27,146 patients with localized prostate cancer are treated with EBRT annually in the US. The cost of standard fractionation in 45 or 39 fractions is US$ 26,782 and 23,625 per patient, respectively. With moderate hypofractionation in 28 or 20 fractions, the cost is US$ 17,793 and 13,402 per patient, respectively. The use of moderate hypofractionation would lead to 25-50% annual savings US$158,315,472-US$363,213,480 in the US.
conclusionsModerate hypofractionation may have the potential to save approximately US$0.16-0.36 billion annually, likely without impacting survival or tolerability. This may lead to lower personal financial toxicity. It would be reasonable for public and private payers to consider which type of radiation is most suited to reimbursement.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.